FundedIQ
Health Care

Solvotrin Therapeutics

Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications. Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities from existing compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk. Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential. The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies.

www.solvotrin.com Cork, Ireland 11-50 employees
Total raised
$6.7M
Rounds
1
Latest
Nov 2020

Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications. Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities from existing compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk. Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential. The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies.

Solvotrin Therapeutics has raised $6.7M across 1 round. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Nov 2, 2020
$6.7M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Solvotrin Therapeutics is featured in

Similar companies

ProVerum Medical

ProVerum Medical is a healthcare company that creates new therapies for benign prostatic hyperplasia (BPH). The company's ProVee System is a minimally invasive implant designed to unblock the urethra without the need for cutting, heating, or removing tissue.

Series B $80.0M
CroíValve

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

Series Unknown $2.9M
Novus Diagnostics

When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million people every year. Our technology platform brings together novel electrochemical sensors, centrifugal microfluidics and automated sample processing and analysis to diagnose and characterise a blood stream infection within 15 minutes; enabling earlier lifesaving targeted treatment. We are a young, driven company working to solve a major global health challenge. We are building a team of people who are excited by this challenge and committed to making a real difference through their work.

Seed $4.7M
SISU Aesthetic Clinic

SISU is a collection of doctor-led, patient-centric aesthetic medical clinics.

Series Unknown $15.0M
Vida Care

Vida Care offers patients the opportunity to easily schedule various routine tests such as blood, cholesterol, cortisol, diabetes, thyroid, hormones, colon cancer, and STIs, with the convenience of receiving results within 48 hours. This program allows patients immediate access to preventative health screening.

Series Unknown $1.0M
Neurent Medical

Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland.

Series Unknown
LaNua Medical

LaNua Medical develop disruptive image-guided technologies providing safe and effective endovascular solutions.

Seed $6.3M
NUA Surgical

NUA Surgical is an award-winning start-up based at the Innovation Hub, Galway on the West Coast of Ireland. The company has invented the patented and specialized surgical retractor to make C-Sections a safer and superior surgery.

Series A $6.9M
SymPhysis Medical

SymPhysis' Medical will likely foster inventive innovations that treat a scope of ongoing infections, putting the patient involvement with the cutting edge of our plan answers for work on personal satisfaction. About SymPhysis MedicalSymPhysis Medical's rising innovation, releaze, is a waste innovation to treat a typical confusion of late-stage tumors, harmful pleural emission (MPE). MPE causes significant windedness and chest torment in up to 15% of patients with malignant growth.

Series Unknown $2.4M
Spectrum Life

Delivering digital solutions for the employer, insurance, and university sectors, SpectrumLife is a mental health and wellbeing innovation with a mission to transform and safeguard as many lives as possible. In Ireland and the UK, SpectrumLife serves 2,500 clients and 25 million consumers. Our clinically supported solutions make sure that there is something for everyone, regardless of where they are on the wellbeing spectrum.

Series B $18.4M
Altach Biomedical

Altach Biomedical, a venture firm under NLC, creates a range of biomimetic cartilage grafts to help surgeons address cartilage abnormalities and enhance the well-being of patients.

Series Unknown $1.3M
Ulysses Neuroscience

Ulysses Neuroscience is a company that offers research and development services to pharmaceutical companies, focusing on accelerating drug discovery efforts for a variety of neurological disorders.

Series Unknown $530k
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.